| abstract |
Compounds useful as inhibitors or PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula (I), where j is 0 or 1; k is 0 or 1; m is 0, 1, 2 or 3; n is 1 or 2; W1 is -O-; or -S(=O)¿t?-, where t is 0, 1 or 2; or -N(R?3)-; W2¿ is -O-CRARB- or is absent; Y is =C(R1a)- or -[N∊(O)k]- where k is 0 or 1; R?A and RB¿ are -H; -F; -CF¿3?; -(C1-C4) alkyl; -(C3-C7) cycloalkyl; phenyl; or benzyl substituted with 0 to 3 substituents R?10; or RA and RB¿ are taken together, but only in the case where m is 1, to form a spiro moiety; R?C and RD¿ have the same meaning as R?A and RB¿ except that one of them must be -H, R?1 and R2¿ are -H; -F; -CI;- CN; -NO¿2?; -(C1-C4) alkyl; -(C2-C4) alkynyl; fluorinated -(C1-C3) alkyl; -OR?16¿; and -C(=O)NR22aR22b; R3 is H; -(C¿1?-C3) alkyl; phenyl; benzyl; or -OR?16; R4, R5 and R6¿ in addition to other meanings may be taken together to form formula (II), G1 is a saturated or unsaturated carbon ring system; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; -G2 is a saturated or unsaturated carbon ring system; wherein one carbon atom of may be replaced by a heteroatom selected from N, O, and S; and E is selected from formula (III). |